Wibke Lembke

Wibke Lembke is a prominent inventor based in Schlieren, Switzerland. She has made significant contributions to the field of medical biotechnology, particularly in the development of innovative therapeutic solutions. Her work focuses on the inhibition of glycosylated IL-17A, a crucial factor in various inflammatory diseases.

Latest Patents

Wibke Lembke holds a patent for "IL-17A binding molecules and medical uses thereof." This invention relates to a polypeptide that inhibits the activity of glycosylated IL-17A. The polypeptide comprises or consists of an amino acid sequence selected from a specific group, allowing for the development of effective medical treatments. The patent also covers fusion constructs, compositions, and medical uses that incorporate this polypeptide. She has 1 patent to her name.

Career Highlights

Wibke Lembke has established herself as a key figure in her field through her innovative research and development efforts. She is currently associated with Covagen AG, where she continues to advance her work in medical biotechnology. Her contributions have the potential to impact the treatment of various diseases significantly.

Collaborations

Wibke collaborates with talented professionals in her field, including Michela Sillacci Melkko and Nadja Banziger. These collaborations enhance the research and development process, leading to more effective solutions in medical biotechnology.

Conclusion

Wibke Lembke is a dedicated inventor whose work in medical biotechnology is paving the way for new therapeutic approaches. Her innovative patent on IL-17A binding molecules exemplifies her commitment to advancing healthcare solutions.

Profile summary based on public USPTO records.